Harish Kumar, Sunil Sharma, Neeru Vasudeva
Harish Kumar*, Sunil Sharma, Neeru Vasudeva
Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India-125001.
Volume - 15,
Issue - 3,
Year - 2022
The research study designed to investigate the nephroprotective efficiency of Calotropis gigantea stem bark extract. Streptozotocin (60 mg/kg/ i.p) diabetes model was used to evaluate the Nephropathy potential of Calotropis gigantea in animals. After single administration of STZ nephropathic complication develops within four weeks. Nephropathy was assessed by blood urea nitrogen, increasing serum creatinine level, microproteinuria, lipid alteration and high renal oxidative stress. Calotropis gigantea stem bark extract shows prominent nephroprotective effect at high dose (500 mg/kg p.o) as compared to low dose treatment (200 mg/kg p.o) in experimentally induced diabetic nephropathy in rats. The present study indicated the plant having of medicinally significant bioactive constituents that shows tremendous nephroprotective effect. It is concluded that stem bark extract of Calotropis gigantea had a role in diabetes control and impedes the continuation of diabetes-induced experimental nephropathy.
Cite this article:
Harish Kumar, Sunil Sharma, Neeru Vasudeva. Plant Calotropis gigantea: Management of Diabetic Nephropathy in Experimentally Induced Diabetes in Rats. Research Journal of Pharmacy and Technology. 2022; 15(3):1090-6. doi: 10.52711/0974-360X.2022.00182
Harish Kumar, Sunil Sharma, Neeru Vasudeva. Plant Calotropis gigantea: Management of Diabetic Nephropathy in Experimentally Induced Diabetes in Rats. Research Journal of Pharmacy and Technology. 2022; 15(3):1090-6. doi: 10.52711/0974-360X.2022.00182 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-3-25
1. Verdini L, Zakaria FR, Prangdimurti E. Analysis of blood glucose and plasma insulin levels of tea and cinnamon tea drink against people with diabetes mellitus type 2. IOSR J Biotechnol and Biochem, 2017; 3(2):48-52.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009; 1; 32(Supplement 1): S62-S77.
3. Bishnoi HK, Mahadevan N, Balakumar P. The combined strategy with PPARα agonism and AT1 receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. Pharmacol Res, 2012; 66(4):349-356.
4. Cho N, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clinc Practice, 2018; 1; 138:271-281.
5. Soldatos G, Cooper ME. Diabetic Nephropathy: important pathophysiologic mechanisms. Diabetic Res Clin Pract 2008; 82: S75-9.
6. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab, 2000; 26:8-14.
7. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol, 2007; 106:26-31.
8. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exper Biol Med. 2008; 233(1):4-11.
9. Balakumar P, Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol, 2010; 56:570-589.
10. Yadav AV, Momin MB, Panjwani Md. Awais. Renoprotective effect of Corallocarpus epigaea in Nephropathy in Wistar Rats. Research J. Pharm. and Tech. 2020; 13(7): 3163-3168. doi: 10.5958/0974-360X.2020.00559.4.
11. Chandiran Sharmila C, Renuka K, Subramanian SP. Biochemical Evaluation of Antidiabetic properties of Strychnos potatorum Seeds extract studied in High Fat Diet Fed- Low dose Streptozotocin induced experimental type 2 diabetes in Rats. Research J. Pharm. and Tech 2020; 13(6):2615-2623. doi: 10.5958/0974-360X.2020.00465.5.
12. Zeeuw D, Remuzzi G, Parving H, Keane F, Zhang Z, Shahinfar S, Snapinn S, Cooper E M, Mitch E W, Brenner M. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from Renaal. Kidney Int. 2004 Jun;65(6):2309-20.
13. Balakumar P, Reddy J, Singh M. Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy? Mol Cell Biochem, 2009; 330:187-192.
14. Rosenson RS, Fioretto P, Dodson PM. Does microvascular disease predict macrovascular events in type 2 diabetes? Atherosclerosis, 2011; 218:13-28.
15. Wani A, Chaudhary J, Jain A. A Study to Evaluate the combined effect of cromolyn Sodium and Fenofibrate in Gentamicin induced Nephropathy. Research J. Pharm. and Tech. 2020; 13(7): 3215-3220. doi: 10.5958/0974-360X.2020.00569.7.
16. Sathyanarayanan G, Shanmugasundaram P, Geetha P. A Prospective Observational Study on Microalbuminuria as Risk factor of Chronic Renal Failure in patients with Type 2 Diabetes. Research J. Pharm. and Tech. 2017; 10(9): 3085-3088. doi: 10.5958/0974-360X.2017.00547.9.
17. Renu A, Saiyada NA, Odenbach S. Effect of reinstitution of good metabolic control on oxidative stress in kidney of diabetic 21 rats. J Diab Compl, 2004; 5:282-288.
18. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998; 339(2):69-75.
19. Kern TS, Berkowitz BA, Feldman EL. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) meeting summary: Advances toward measuring diabetic retinopathy and neuropathy: from the bench to the clinic and back again (April 4–5, 2007, Baltimore, Maryland). J Diab Compl, 2009; 23(3):219-23.
20. Mitra A, Chakraborty S, Auddy B, Tripathi P, Sen S, Saha AV, et al. Evaluation of chemical constituents and free-radical scavenging activity of Swarnabhasma (gold ash), an ayurvedic drug. J Ethnopharmacol, 2002; 80(2-3):147-153.
21. Chetty M, Sivaji K, Rao. 2008. Flowering plants of Chittor district Andhra Pradesh. 1th ed. Tirupati, India: Published by Student Offset Printer 202.
22. Nanu R, Raghuveer I, Chandra RC. Prevention of high fructose diet induced Insulin resistance by Nyctanthes arbortristis and Calotropis gigantea in rats. Pharmacognosy Magazine, 2009; 1(5):58-63.
23. Thakur S, Das P, Itoh T. Kazunori Imai, Taro M. Latex extractable of Calotropis gigantea. Phytochem, 1984; 9:2085-2087.
24. Sen S, Sahu NP, Mahato SB. Flavonol glycosides from Calotropis gigantea. Phytochem, 1992; 31(8):2919-2921.
25. Sengupta A, Bhattacharya D, Pal G, Sinha NK. Comparative studies calotropin DI and DII from the latex of Calotropis gigantea. Arch Biochem Biophys, 1984; 1:17-25.
26. Habib MR, Nikkon F, Rahman M, Haque ME, Karim MR. Isolation of stigmasterol and beta-sitosterol from methanolic extract of root bark of Calotropis gigantea (Linn). Pak J Biol Sci, 2007; 10(22):4174-4176.
27. Seeka C, Sutthivaiyakit S. Cytotoxic cardenolides from the leaves of Calotropis gigantea. Chem Pharm Bull (Tokyo), 2010; 58(5):725-728.
28. Wang ZN, Wang MY, Mei WL, Han Z, Dai HF. A new cytotoxic pregnanone from Calotropis gigantea. Mol, 2008; 13(12):3033-3039.
29. Chitme HR, Chandra M, Kaushik S. Studies on anti-diarrhoeal activity of Calotropis gigantea R.Br. in experimental animals. J Pharma Pharm Sci, 2004; 7(1):70-75.
30. Chitme HR, Chadra R, Kaushik S. Evaluation of analgesic activities of Calotropis gigantea extract in vivo. Asia Pacific J Pharmacol, 2005; 16:35-40.
31. A. Argal, AK. Pathak, J. Ethnopharmacol 106(1):142-145 (2006).
32. Pathak AK, Argal A. Analgesic activity of Calotropis gigantea flower. Fitoterapia 2007; 78(1):40-42.
33. Srivastava SR, Keshri G, Bhargavan B, Singh C, Singh MM. Pregnancy interceptive activity of the roots of Calotropis gigantea Linn. in rats. Contraception, 2007; 75(4):318-322.
34. Rajesh R, Raghavendra Gowda CD, Nataraju A, Dhananjaya BL, Kemparaju K, Vishwanath BS. Procoagulant activity of Calotropis gigantea latex associated with fibrin(ogen)olytic activity. Toxicon, 2005; 46(1):84-92.
35. Singh S, Bharti N, Chugh M, Naqvi F, Azam A. Activity of extracts and procesterol from Calotropis gigantea against Entamoeba histolytica. Nat Prod Commun, 2010; 5(6):867-868.
36. Deshmukh PT, Fernandes J, Atul A, Toppo E. Wound healing activity of Calotropis gigantea root bark in rats. J Ethnopharmacol, 2009; 125(1):178-181.
37. Jose H, Krishnakumar K, Dinesh Kumar B. Herbal Extracts based Scaffolds for Wound Healing Therapy. DOI 10.5958/0974-360X.2021.00320.6.
38. Lodhi G, Singh HK, Pant KK, Hussain Z. Hepatoprotective effects of Calotropis gigantea extract against carbon tetrachloride induced liver injury in rats. Acta Pharm, 2009; 59(1):89-96.
39. Bedekar A, Shah K, Koffas M. Natural products for type II diabetes treatment. Adv Appl Microbiol, 2010; 71:21-73.
40. Kadali SLDV RM, Das MC, Bayya MHRK G, Vijay Kumar M. Preliminary Phytochemical Screening and Evaluation of effect of aqueous and Ethanolic leaf extracts of Chloroxylon swietenia on blood glucose in Streptozotocin Induced Diabetic rats. Research J. Pharm. and Tech. 2019; 12(11):5495-5500. doi: 10.5958/0974-360X.2019.00917.X.
41. Shastry V.M, Patil V.R, Chaudhari R.Y. Evaluation of Acute and Chronic Anti-Inflammatory Activity of Whole Plant of Calotropis gigantea in Various Experimental Animal Models. Research J. Pharm. and Tech. 4(5): May 2011; Page 815-818.
42. Wadekar JB, Sawant RL, Sanklecha KR, Ghodechor AS, Sable PB, Barkade GD. Anticoagulant activity of Calotropis gigantea leaves. Research J. Pharm. and Tech 2016; 9(9):1493-1495. doi: 10.5958/0974-360X.2016.00290.0.
43. Biswasroy P, Panda S, Das D, Kar DM, Ghosh G. Pharmacological investigation of Calotropis gigantea: A benevolent herb of Nature. Research J. Pharm. and Tech. 2020; 13(1): 461-467. doi: 10.5958/0974-360X.2020.00090.6.
44. Aruna P, Gayathiri N. M. Cardioprotective Activity of Telmisartan, Metformin and its Combination against Doxorubicin Induced Myocardial Infarction in Rat Model. Research J. Pharm. and Tech 2018; 11(12): 5293-5296. doi: 10.5958/0974-360X.2018.00964.2
45. Lyman JL. Blood urea nitrogen and creatinine. Emergency Med Clinics North Am, 1986; 4:223–33.
46. Finco DR, Duncan JR. Evaluation of blood urea nitrogen and serum creatinine concentrations as indicators of renal dysfunction: A study of 111 cases and a review of related literature. J Am Vet Med Assoc. 1976 Apr 1;168 (7):593-601.
47. Morsy MD, Hassan WN, Zalat SI. Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats. Diabetol Metab Syndrome, 2010; 2:29-39.
48. Remuzzi A, Puntorieri S, Alfano M, Macconi D, Abbate M, Bertani T, et al. Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Laboratory Investig, 1992; 67:572–589.
49. Schrijvers BF, De Vriese AS. Novel insights in the treatment of diabetic nephropathy. Acta Clinica Belgica, 2007; 62:278–290.
50. Hirasawa Y, Sakai T, Ito M, Yoshimura H, Feng Y, Nagamatsu T. Advanced glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway. Eur J Pharmacol, 2011; 672:159–68.
51. Thompson J, Wilson P, Brandewie K, Taneja D, Schaefer L, Mitchell B, et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathology, 2011; 179:1179–1187.
52. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia, 2012; 125-012-2578-1.
53. Chowdary P R, Praveen. D, Aanandhi V M. A Prospective Study on Incidence of Dyslipidemia in Diabetes Mellitus. Research J. Pharm. and Tech. 2017; 10(2):431-433. doi: 10.5958/0974-360X.2017.00086.5
54. Balakumar P, Arora MK, Reddy J, Anand-Srivastava MB. Pathogenesis of diabetic nephropathy: involvement of multifaceted signalling mechanism. J Cardiovasc Pharmacol, 2009; 54:129-138.
55. Rysavá R, Tesar V, Merta M. The Czech Group for the Study of Glomerulonephritis. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Pressure Monitoring, 2005; 10:207–213.
56. Barnett A. Preventing renal complications in type 2 diabetes: Results of the diabetics exposed to telmisartan and enalapril trial. J Am Society Nephrol, 2006; 17:S132–S145.
57. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: A post hoc analysis of the Incipient To Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (Innovation) study. Hypertension Res, 2008; 31:657–664.
58. Bakris G, Burgess E, Weir M, Davidai G, Koval S. AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int, 2008; 74:364–379.
59. Toth PP. Review of the AMADEO study: reducing proteinuria in patients with diabetic nephropathy with telmisartan versus losartan. Commentary. Postgraduate Med, 2010; 122:165–178.
60. McCarty MF. Adjuvant strategies for prevention of glomerulosclerosis. Medical Hypotheses, 2006; 67:1277–1296.
61. Dursun E, Dursun B, Suleymanlar G, Ozben T. Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus. Acta Diabetol, 2005; 42:123–138.
62. Roy S, Sehgal R, Padhy BM, Kumar VL. Antioxidant and protective effect of latex of Calotropisprocera against alloxan-induced diabetes in rats. J Ethnopharmacol, 2005; 102(3):470-473.
63. Mariee AD, Abd-Allah GM, El-Yamany MF. Renal oxidative stress and nitric oxide production in streptozotocin-induced diabetic nephropathy in rats: the possible modulatory effects of garlic (Allium sativum L.). Biotechnol Appl Biochem, 2009; 52:227–232.
64. Arora MK, Reddy K, Balakumar P. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. Eur J Pharmacol, 2010; 636:137–144.